Multiple Myeloma Clinical Trials
A listing of Multiple Myeloma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found 11 clinical trials
Daratumumab and Belatacept for Desensitization
Some kidney transplant candidates have a very low chance of getting a kidney transplant because their immune systems are "highly sensitized" to most kidney donors. Being "highly sensitized" means that they will likely have to wait a long time (more than 5 years) before an acceptable donor is found for …
- 0 views
- 02 Dec, 2021
- 1 location
Study of Magrolimab Combinations in Participants With Relapsed/Refractory Multiple Myeloma
recommended Phase 2 dose (RP2D) of magrolimab in participants with relapsed/refractory multiple myeloma (MM) for the following combinations: magrolimab + daratumumab, magrolimab + pomalidomide + dexamethasone
- 0 views
- 27 Nov, 2021
- 1 location
Treatment of Selinexor in Combination With Clarithromycin Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients
relapsed/refractory multiple myeloma. The hypothesis is that the addition of Selinexor to Clarithromycin, Pomalidomide and Dexamethasone will increase the overall response rate of patients with relapsed
- 0 views
- 28 Nov, 2021
- 2 locations
Geriatric-assessment Interventions to Address Functional Deficits in Older Adults w Multiple Myeloma
Myeloma is the second most common type of blood cancer in the United States. Myeloma most commonly affects older adults. While some younger individuals do get myeloma, the average age when
- 0 views
- 01 Dec, 2021
- 1 location
Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple Myeloma
The purpose of this study is to infuse BCMA CAR-NK cellsUmbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells to the patients with relapsed and refractory multiple myeloma (MM), to
- 0 views
- 28 Nov, 2021
- 1 location
Clinical Trial for Autologus NK Cells Alone or in Combination With Isatuximab as Maintenance for Multiple Myeloma
CellProtect as compared to Isatuximab for the treatment of patients with newly diagnosed multiple myeloma who are eligible for stem cell transplantation (SCT) as maintenance after SCT.
- 0 views
- 02 Dec, 2021
- 1 location
Isatuximab in Patients With Monoclonal Gammopathy of Renal Significance
treatment of adult patients with multiple myeloma, but it is not approved by the FDA to treat MGRS. This means that the use of isatuximab in this study is considered 'investigational'.
- 0 views
- 02 Dec, 2021
- 2 locations
A Study of Fedratinib With IDH Inhibition in Advanced-Phase IDH-Mutated Ph-Negative Myeloproliferative Neoplasms
The purpose of this research is to gather information on the safety and effectiveness of fedratinib (a drug called a "jak inhibitor" ) in combination with ivosidenib or enasidenib (two anti-cancer drugs). While all three drugs are FDA-approved for various conditions, the US Food and Drug Administration (FDA) has not …
- 0 views
- 29 Nov, 2021
- 1 location
MGRS: Clinical-histological Features of a Multicenter Case Series
The term "Monoclonal Gammopathies of Renal Significance" (MGRS) describes a group of diseases characterized by the presence of an immunoglobulin or monoclonal immunoglobulin fraction that has the ability to cause renal damage. It is important to diagnose MGRS correctly and early as renal survival depends on the renal function present …
- 0 views
- 21 Nov, 2021
- 8 locations
Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies
This study examines the quality of life in patients with monoclonal gammopathy of unknown significance and smoldering multiple myeloma. Collecting quality of life information from patients may
- 0 views
- 01 Dec, 2021
- 1 location
- 1
- 2